Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 30;25(1):133.
doi: 10.1007/s10238-025-01666-3.

A unifying model for multiple sclerosis

Affiliations
Review

A unifying model for multiple sclerosis

Daniel Jonathan Park. Clin Exp Med. .

Abstract

Multiple sclerosis (MS) is a complex neurodegenerative disorder with unresolved cause that has been the subject of intensive research. A variety of putative models have been proposed to explain the course of disease. The preeminent mechanisms are suggested to be based on autoimmunity, including via viral epitope mimicry, although difficulties with a classical autoimmunity model for MS have been described. One prior idea that incorporates consideration of viral-self-cross-reactivity is that reactivated HHV-6A virus might induce subsequent reactivation of another virus, EBV, in a relay, resulting in a cascade of downstream consequences. Here, an alternative model for MS is proposed. This posits a viral reactivation relay in which EBV reactivation in the brain precedes HHV-6A reactivation in oligodendrocytes and neurons. At this juncture, relapsing-remitting MS (RRMS) can ensue to generate characteristic lesions, dominated by outbreaks of viral reactivation and CD8+T-cell-mediated cytotoxicity and inflammation. Additionally, self-targeting antibodies can be raised to mark the onset of progressive MS in a subset of patients. This model harmonises a plethora of prior evidence from diverse fields. It is suggested that future studies should challenge this new model for MS and that it provides direction for future approaches to prevention and therapy.

Keywords: Autoantibodies; Cytotoxicity; Disease model; EBV; HHV-6A; Multiple sclerosis; Progressive MS; RRMS; Viral reactivation.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: Not applicable. Ethical approval and consent to participate: Not applicable. Consent for publication: Not applicable.

References

    1. Multiple LH, Pathology S. Multiple sclerosis pathology. Cold Spring Harb Perspect Med. 2018;8:a028936. - PMC - PubMed
    1. Antel J, Antel S, Caramanos Z, Arnold DL, Kuhlmann T. Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity? Acta Neuropathol. 2012;123:627–38. - PubMed
    1. Lassmann H. Pathogenic mechanisms associated with different clinical courses of multiple sclerosis. Front Immunol. 2019;9:3116. - PMC - PubMed
    1. Fraussen J, de Bock L, Somers V. B cells and antibodies in progressive multiple sclerosis: contribution to neurodegeneration and progression. Autoimmun Rev. 2016;15(9):896–9. - PubMed
    1. Callegari I, Oechtering J, Schneider M, Perriot S, Mathias A, Voortman MA, et al. Cell-binding IgM in CSF is distinctive of multiple sclerosis and targets the iron transporter SCARA5. Brain. 2024;147(3):839–48. - PMC - PubMed

MeSH terms